The content on this site is intended for healthcare professionals only
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA ge...
Dr Hedy Kindler - University of Chicago, Chicago, USA
2 Jun 2019
Maintenance therapy with PARP inhibitor olaparib delays progression in patients ...
Dr Hedy Kindler - University of Chicago, Chicago, USA
2 Jun 2019
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients...
Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA
2 Jun 2019
Epigenetic expression in T cell leukaemia
Dr Sinisa Dovat - Penn State Cancer Institute, Hershey, USA
24 May 2019
B-lymphoid transcriptional programme as a barrier against malignant transformati...
Prof Markus Müschen - City of Hope Comprehensive Cancer Center, Los Angeles, USA
24 May 2019
Emerging role of radioembolization for hepatocellular carcinoma
Prof Riad Salem - Northwestern University, Chicago, USA
8 May 2019
Advanced HCC: New systemic treatment options
Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt
8 May 2019
Surgical management of pancreatic cancer
Prof Ibrahim Al-Sheneber - Saudi Cancer Foundation, Khobar, Saudi Arabia
8 May 2019
Highlights from IGILUC 2019
Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt
8 May 2019
PARP inhibitors and their side effects in solid tumour therapy
Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA
8 May 2019
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases
Dr Marina Garassino - National Tumor Institute, Milan, Italy
15 Apr 2019
Immune checkpoint inhibitor combination efficacious for patients with high-grade...
Prof Sandip Patel - UC San Diego, San Diego, USA
11 Apr 2019